From initial discovery to market-ready product, biotech development is a complex multi-phase process, where strategic partnerships, continuous innovation and careful navigation of regulatory landscapes are crucial for long-term success. Despite this complexity (or perhaps because of it), entrepreneurs and VCs seldom take a step back to consider the full trajectory of this journey. In this article, we’ll explore the typical life cycle of a biotech startup, examining the key milestones and hurdles encountered along the way.
Like two sides of the same coin, industry and academia are each aiming to progress science. On their own, they accomplish great results, but only together can they really drive innovation. One way to reap the fruits from this partnership are endowed chairs. By exchanging resources and independence for publicity and innovative insights, both can contribute to a happier and healthier society.
Sepsis is a serious condition where the body responds improperly to an infection. Every 2.8 seconds, someone dies of sepsis globally, yet no direct therapies exist beyond supportive care. Many clinical trials have investigated the role of Tumor Necrosis Factor (TNF) as a potential therapeutic target, but anti-TNF therapy has not proven to be a breakthrough in the sepsis field. Therefore, understanding how TNF triggers this devastating condition could be of help for millions of people worldwide.
Ghent, February 26, 2025 — 4Tissue, a pioneer in biotechnology that is revolutionizing regenerative medicine, has successfully completed an additional €1.5M funding round, consisting of €1M in equity investments and additional grants. This funding will support the further development of the company’s groundbreaking bioresorbable hydrogel technology, which has the potential to significantly improve breast reconstruction and other tissue regeneration applications. This represents an important step forward in the evolution of regenerative medicine, with a particular focus on women’s health.
Microfluidics is a technology that allows researchers to precisely manipulate and control tiny amounts of fluids within networks of channels typically smaller than a human hair. The approach is now achieving the extreme miniaturization necessary to truly enter the ‘lab-on-a-chip’ era, with profound implications for biological research and human health.
Meeting the needs of a growing global population while addressing the clear demand for a more sustainable food supply is challenging but not impossible. Innovative biotechnological tools are constantly being created, and they are increasingly available on the market. However, the industry is in desperate need of support, as EU legislation can act as more of a hurdle than a facilitator, hindering local advancement. flanders.bio is committed to advocating for the sector and highlights the most pressing challenges in their latest policy paper.
In line with its stellar name, AstriVax Therapeutics is a rising star in Belgian biotech. The company launched in 2022 with €30 million – the largest seed round ever raised by a KU Leuven spin-out – and rapidly became a clinical-stage company, using its plug-and-play platform to fast-track development of vaccines and immunotherapies.
Ghent, Belgium, 15 January 2025 – ONTOFORCE, a leader in semantic technology for life sciences, headquartered in Ghent, Belgium, and Rancho Biosciences, the leading data science services company headquartered in San Diego, California, have announced a joint collaboration. This partnership aims to transform high quality data-driven research and drug development, providing scientists with unparalleled insights that drive discovery and innovation in the life sciences.
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions.
Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network.
Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncology.
As 2025 comes peeking around the corner, we invite you to look back with us at some of the most exciting science topics we covered this year. From advances in women’s health, organoids, and organ-on-a-chip models to the challenges of data science and innovations in animal science and sustainable biotech; let us walk you through the Benelux life sciences landscape of 2024 as we reflect on the vast amount of knowledge and know-how characteristic to this region.
From initial discovery to market-ready product, biotech development is a complex multi-phase process, where strategic partnerships, continuous innovation and careful navigation of regulatory landscapes are crucial for long-term success. Despite this complexity (or perhaps because of it), entrepreneurs and VCs seldom take a step back to consider the full trajectory of this journey. In this article, we’ll explore the typical life cycle of a biotech startup, examining the key milestones and hurdles encountered along the way.
Like two sides of the same coin, industry and academia are each aiming to progress science. On their own, they accomplish great results, but only together can they really drive innovation. One way to reap the fruits from this partnership are endowed chairs. By exchanging resources and independence for publicity and innovative insights, both can contribute to a happier and healthier society.
Sepsis is a serious condition where the body responds improperly to an infection. Every 2.8 seconds, someone dies of sepsis globally, yet no direct therapies exist beyond supportive care. Many clinical trials have investigated the role of Tumor Necrosis Factor (TNF) as a potential therapeutic target, but anti-TNF therapy has not proven to be a breakthrough in the sepsis field. Therefore, understanding how TNF triggers this devastating condition could be of help for millions of people worldwide.
Ghent, February 26, 2025 — 4Tissue, a pioneer in biotechnology that is revolutionizing regenerative medicine, has successfully completed an additional €1.5M funding round, consisting of €1M in equity investments and additional grants. This funding will support the further development of the company’s groundbreaking bioresorbable hydrogel technology, which has the potential to significantly improve breast reconstruction and other tissue regeneration applications. This represents an important step forward in the evolution of regenerative medicine, with a particular focus on women’s health.
Microfluidics is a technology that allows researchers to precisely manipulate and control tiny amounts of fluids within networks of channels typically smaller than a human hair. The approach is now achieving the extreme miniaturization necessary to truly enter the ‘lab-on-a-chip’ era, with profound implications for biological research and human health.
Meeting the needs of a growing global population while addressing the clear demand for a more sustainable food supply is challenging but not impossible. Innovative biotechnological tools are constantly being created, and they are increasingly available on the market. However, the industry is in desperate need of support, as EU legislation can act as more of a hurdle than a facilitator, hindering local advancement. flanders.bio is committed to advocating for the sector and highlights the most pressing challenges in their latest policy paper.
In line with its stellar name, AstriVax Therapeutics is a rising star in Belgian biotech. The company launched in 2022 with €30 million – the largest seed round ever raised by a KU Leuven spin-out – and rapidly became a clinical-stage company, using its plug-and-play platform to fast-track development of vaccines and immunotherapies.
Ghent, Belgium, 15 January 2025 – ONTOFORCE, a leader in semantic technology for life sciences, headquartered in Ghent, Belgium, and Rancho Biosciences, the leading data science services company headquartered in San Diego, California, have announced a joint collaboration. This partnership aims to transform high quality data-driven research and drug development, providing scientists with unparalleled insights that drive discovery and innovation in the life sciences.
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions.
Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network.
Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncology.
As 2025 comes peeking around the corner, we invite you to look back with us at some of the most exciting science topics we covered this year. From advances in women’s health, organoids, and organ-on-a-chip models to the challenges of data science and innovations in animal science and sustainable biotech; let us walk you through the Benelux life sciences landscape of 2024 as we reflect on the vast amount of knowledge and know-how characteristic to this region.